Jennifer Schranz

Title: Jennifer Schranz: Innovator in Plasma Kallikrein Inhibitors

Introduction

Jennifer Schranz is a notable inventor based in King of Prussia, PA (US). She has made significant contributions to the field of medicine, particularly in the treatment of hereditary angioedema. Her innovative work has led to the development of a patent that addresses critical health issues faced by patients.

Latest Patents

Jennifer holds a patent for "Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack." This patent provides details on plasma kallikrein antibodies that bind to active plasma kallikrein. The methods described in her patent involve treating and preventing hereditary angioedema attacks, which may include a first treatment period and, optionally, a second treatment period. Additionally, the patent outlines methods for administering a single dose of the antibody to subjects who have undergone prior HAE treatment, followed by multiple doses if the subject experiences an HAE attack after the initial dose. She has 1 patent to her name.

Career Highlights

Jennifer is currently associated with Takeda Pharmaceutical Company Limited, where she continues to advance her research and development efforts. Her work is pivotal in enhancing treatment options for patients suffering from hereditary angioedema.

Collaborations

Jennifer has collaborated with esteemed colleagues, including Burt Adelman and Yung Chyung. These partnerships have fostered a collaborative environment that promotes innovation and the sharing of ideas.

Conclusion

Jennifer Schranz is a remarkable inventor whose work in plasma kallikrein inhibitors has the potential to significantly improve the lives of those affected by hereditary angioedema. Her contributions to the field of medicine exemplify the impact of innovation in healthcare.